A Binding Partnership- Leader Life Sciences with Diagnostic Biosystem
It is in a pathologist’s nature to take a closer look. The more intimate and in-depth the look, the more precise the diagnosis is, of course. This clarity and visibility are provided with the help of various high-quality primary antibodies, detection chemistries, and a wide range of ancillaries and chromogens, complemented with automated IHC Stainers.
All of which are specialized by our brand-new partner Diagnostic Biosystem. Founded in 1994 by Dr. Bipin Gupta with a vision of providing high-quality, innovative anatomic pathology reagents to improve the practice of pathology. This partnership essentially enhances our ability to support the region’s histopathologist with immunohistochemistry reagents and primary antibodies.
New antibodies developed by Diagnostic BioSystems go through a rigorous development process to ensure the laboratory is provided with the right tools for a pathologist’s highly technical and ever-changing job. With the threat of new and old diseases always hanging in the air, having the right tools ensures that timely diagnosis and prognosis are achieved. In addition, DBS products and procedures are validated to the ISO 13485 medical device standard, ensuring lot-to-lot reliability and performance.
This alliance hopes to expand our pathology vertical and give the laboratory a comprehensive solution that will make its process efficient and effective. Through the combination of ready-to-use kits, antibodies, instrumentation, and novel chromogens, Diagnostic BioSystems provides a complete suite of IHC products for clinical diagnosis.
Immunohistochemistry methods are a crucial element in the advancement of a cancer diagnosis. It is extensively and routinely used in pathology laboratories. Mutation testing by IHC may offer several potential advantages such as faster turn-around-time, comparatively cheaper than other testing and requiring minimal tissue. This becomes an added advantage in cases of low tumoral cellularity and allows the diagnosis of individual antigen-bearing tumor cells with minimum risk of potential contamination.
To understand this better, we have to deep dive into the workflow of immunohistochemistry:
Once the sample is collected and prepared for recognition, primary antibodies react with the antigen in the tissue. The antibodies are usually linked to an enzyme or a fluorescent dye. After the antibodies bind to the antigen in the tissue sample, the enzyme or dye is activated, and the antigen can then be seen under a microscope.
From sample prep to image acquisition, the Diagnostic biosystem provides a varied range of reagents and accessories that will give accurate results for this diagnostic research and more. In addition, adding these reagents to our portfolio will provide pathologists the convenience when searching for critical immunoreagents for their use in the vitro diagnostic assays.
In addition to this, Diagnostic BioSystems offers a fully automated Slide Staining System, the HighLighter™ Automated Slide Stainer. This enables the diagnosticians to save time and prevent human error in the manual staining methods.
The inclusion of this array of solutions from Diagnostic Biosystem with our other pathology automation solutions would make Leader Life Sciences a one-stop shop for all pathology needs. Moreover, it will ensure that the region’s diagnosticians are equipped with the best tools to effectively conduct their clinical diagnoses. We are excited about this binding partnership that will make a pathologist’s life easier and provide accurate diagnosis and prognosis for them.
To learn more about these exciting solutions, mail us at marketing@leaderlifesciences.com.
